Clinical Trials
7 trialsNCT00084487 2014-05-23
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00004189 2013-02-11
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005085 2013-02-11
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006102 2013-02-05
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005817 2013-02-01
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087204 2013-01-23
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00086983 2013-01-10
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated